share_log
Benzinga ·  May 6 07:39
EyePoint Pharmaceuticals Shares Are Trading Lower After the Company's Phase 2 PAVIA Trial of DURAVYU Did Not Meet Its Pre-specified Primary Endpoint
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment